Cardioprotection During Myocardial Infarction in Diabetic Cardiomyopathy
Diabetic cardiomyopathy (DCM) significantly increases the risk of acute myocardial infarction and attenuates or abolishes the cardioprotective effects of several therapeutic approaches. Whether intravenous atorvastatin administration during ongoing acute myocardial infarction retains its cardioprotective potential in the presence of DCM was investigated. Intravenous atorvastatin during ischemia reduces infarct size and preserves cardiac function in DCM rats. The efficacy of this intravenous statin formulation in DCM supports its development as a viable therapeutic option for clinical use.
Authors
- Lina Badimón (ORCID: https://orcid.org/0000-0002-9162-2459)
- Sebastià Alcover (ORCID: https://orcid.org/0000-0003-3699-1769)
- Natàlia Muñoz‐García (ORCID: https://orcid.org/0000-0002-2982-8982)
- Rosa Suades (ORCID: https://orcid.org/0000-0002-0193-3115)
- Alex Gallinat (ORCID: https://orcid.org/0000-0002-1521-2175)
- Gemma Vilahur (ORCID: https://orcid.org/0000-0002-2828-8873)
- Sergi López-Bernal (ORCID: https://orcid.org/0000-0003-1794-879X)
- Lisaidy Ramos-Regalado (ORCID: https://orcid.org/0009-0004-3512-8474)
Institutions
- Instituto de Salud Carlos III (ES)
- Hospital de Sant Pau (ES)
- Institut de Biologia Molecular de Barcelona (ES)
- Institut de Recerca Sant Pau (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Diabetes
- Published
- 2025-03-13
- DOI
- https://doi.org/10.2337/db24-0510
- Citations
- 3
- Primary Topic
- Cardiovascular Function and Risk Factors
- Type
- article
- Field-Weighted Citation Impact
- 4.16